
The other shoe drops for Gossamer’s GB001
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.

One chance for Glaxo’s triple
The UK company's triple combo just got US approval, and now the group must meet rising analyst expectations.